{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:07Z","timestamp":1787020207112,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Janssen Scientific Affairs, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12888-017-1358-3","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T07:38:26Z","timestamp":1496389106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2380-1495","authenticated-orcid":false,"given":"Dominic","family":"Pilon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Muser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon","family":"Kamstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kruti","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,2]]},"reference":[{"issue":"9904","key":"1358_CR1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","volume":"382","author":"HA Whiteford","year":"2013","unstructured":"Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575\u201386.","journal-title":"Lancet"},{"key":"1358_CR2","doi-asserted-by":"crossref","unstructured":"Cloutier M, Sanon Aigbogun M, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016.","DOI":"10.4088\/JCP.15m10278"},{"key":"1358_CR3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth edn, DSM-5","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Schizophrenia spectrum and other psychotic disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth edn, DSM-5; 2013. p. 102."},{"issue":"5","key":"1358_CR4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.1993.01820170047006","volume":"50","author":"J Lieberman","year":"1993","unstructured":"Lieberman J, Jody D, Geisler S, Al E. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993;50(5):369\u201376.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1358_CR5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00406-006-0683-1","volume":"257","author":"M J\u00e4ger","year":"2007","unstructured":"J\u00e4ger M, Riedel M, Messer T, Laux G, Pfeiffer H, Naber D, et al. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci. 2007;257(1):47\u201353.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"1358_CR6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/2045125312474019","volume":"3","author":"K Higashi","year":"2013","unstructured":"Higashi K, Medic G, Littlewood KJ, Diez T, Granstr\u00f6m O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200\u201318.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"3","key":"1358_CR7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/j.2051-5545.2008.tb00182.x","volume":"7","author":"PD McGorry","year":"2008","unstructured":"McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry. 2008;7(3):148\u201356.","journal-title":"World Psychiatry"},{"issue":"1","key":"1358_CR8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1751-7893.2008.00108.x","volume":"3","author":"PL Quach","year":"2009","unstructured":"Quach PL, Mors O, Christensen TO, Krarup G, Jorgensen P, Bertelsen M, et al. Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder. Early Interv Psychiatry. 2009;3(1):66\u201374.","journal-title":"Early Interv Psychiatry."},{"issue":"2","key":"1358_CR9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.9758\/cpn.2011.9.2.45","volume":"9","author":"BJ Miller","year":"2011","unstructured":"Miller BJ, Bodenheimer C, Crittenden K. Second-generation antipsychotic discontinuation in first episode psychosis: An updated review. Clin Psychopharmacol Neurosci. 2011;9(2):45\u201353.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"1358_CR10","first-page":"119","volume":"9","author":"G Medic","year":"2012","unstructured":"Medic G, Higashi K, Littlewood KJ, Diez T, Granstrom O, Kahn RS. Dosing frequency and adherence in chronic psychiatric disease: Systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012;9:119\u201331.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"1358_CR11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2146\/ajhp140219","volume":"72","author":"M-H Lafeuille","year":"2015","unstructured":"Lafeuille M-H, Grittner AM, Fortier J, Muser E, Fasteneau J, Duh MS, et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am J Health Pharm. 2015;72(5):378\u201389.","journal-title":"Am J Health Pharm"},{"issue":"1","key":"1358_CR12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1744-859X-10-10","volume":"10","author":"T Lambert","year":"2011","unstructured":"Lambert T, Olivares JM, Peuskens J, Desouza C, Kozma CM, Otten P, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann General Psychiatry. 2011;10(1):10.","journal-title":"Ann General Psychiatry"},{"issue":"2","key":"1358_CR13","first-page":"266","volume":"5","author":"P Chue","year":"2005","unstructured":"Chue P, Llorca P, Duchesne I, Leal A, Rosillon D, Mehnert A. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res Clin Exp Ther. 2005;5(2):266.","journal-title":"J Appl Res Clin Exp Ther"},{"issue":"9","key":"1358_CR14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.18553\/jmcp.2015.21.9.754","volume":"21","author":"SC Marcus","year":"2015","unstructured":"Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. J Manag Care Spec Pharm. 2015;21(9):754\u201369.","journal-title":"J Manag Care Spec Pharm"},{"key":"1358_CR15","unstructured":"Invega Sustenna (paliperidone palmitate) extended-release injectable suspension US prescribing information. Titusville: Janssen Pharmaceuticals, Inc.; 2015. http:\/\/www.janssencns.com\/shared\/product\/invegasustenna\/prescribing-information.pdf . Accessed Oct 2016."},{"issue":"4","key":"1358_CR16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2045125311413006","volume":"1","author":"CA Bossie","year":"2011","unstructured":"Bossie CA, Fu D-J, Sliwa JK, Alphs L, Ma Y-W. Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial. Ther Adv Psychopharmacol. 2011;1(4):111\u201324.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1\u20133","key":"1358_CR17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","volume":"169","author":"A Schreiner","year":"2015","unstructured":"Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1\u20133):393\u20139.","journal-title":"Schizophr Res"},{"key":"1358_CR18","doi-asserted-by":"crossref","unstructured":"Alphs L, Bossie C, Mao L, Lee E, Starr HL. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement. Early Interv Psychiatry. 2015;(June 2010):1\u201311.","DOI":"10.1111\/eip.12271"},{"key":"1358_CR19","unstructured":"Medicaid Drug Rebate Program. Centers for Medicare and Medicaid Services. 2016. https:\/\/www.medicaid.gov\/Medicaid-CHIP-Program-Information\/By-Topics\/Benefits\/Prescription-Drugs\/Medicaid-Drug-Rebate-Program.html . Accessed Oct 2016."},{"issue":"5","key":"1358_CR20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"key":"1358_CR21","doi-asserted-by":"crossref","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;42(11):1130\u20139.","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"1358_CR22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/B978-0-12-179060-8.50007-4","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1977","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. New York, Toronto: Academic Press Inc.; 1977. p. 19\u201374."},{"issue":"6","key":"1358_CR23","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228\u201334.","journal-title":"Commun Stat Simul Comput"},{"key":"1358_CR24","unstructured":"Elixhauser A, Steiner C, Kruzikas. D. HCUP Methods Series Report # 2004\u20131. ONLINE February 6, 2004. U.S. Agency for Healthcare Research and Quality. [Internet]. Comorbidity Software Documentation. Rockville, MD, USA; 2004 [cited 2013]. p. 12\u20135. Available from: http:\/\/www.hcup-us.ahrq.gov\/reports\/ComorbiditySoftwareDocumentationFinal.pdf ."},{"issue":"5","key":"1358_CR25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3111\/13696998.2014.1001514","volume":"18","author":"O Baser","year":"2014","unstructured":"Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ. 2014;18(5):357\u201365.","journal-title":"J Med Econ"},{"issue":"2","key":"1358_CR26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2217\/cer.14.50","volume":"4","author":"EH Morrato","year":"2015","unstructured":"Morrato EH, Parks J, Campagna EJ, Muser E, Thomas DSK, Fang H, et al. Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence. J Comp Eff Res. 2015;4(2):89\u201399.","journal-title":"J Comp Eff Res"},{"key":"1358_CR27","first-page":"1","volume":"14","author":"Y Xiao","year":"2015","unstructured":"Xiao Y, Muser E, Lafeuille M-H, Pesa J, Fastenau J, Duh MS, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients. J Comp Eff Res. 2015;14:1\u201314.","journal-title":"J Comp Eff Res"},{"issue":"4","key":"1358_CR28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40801-015-0043-4","volume":"2","author":"JA Pesa","year":"2015","unstructured":"Pesa JA, Muser E, Montejano LB, Smith DM, Meyers OI. Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics. Drugs-Real World Outcomes. 2015;2(4):377\u201385.","journal-title":"Drugs-Real World Outcomes"},{"key":"1358_CR29","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0924-9338(14)70001-X","volume":"29","author":"S Heres","year":"2014","unstructured":"Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry. 2014;29:1409\u201313.","journal-title":"Eur Psychiatry"},{"issue":"10","key":"1358_CR30","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0269881109104882","volume":"24","author":"MX Patel","year":"2010","unstructured":"Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists\u2019 use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol. 2010;24(10):1473\u201382.","journal-title":"J Psychopharmacol"},{"issue":"6","key":"1358_CR31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/2045125315612013","volume":"5","author":"R Emsley","year":"2015","unstructured":"Emsley R, Alptekin K, Azorin J-M, Canas F, Dubois V, Gorwood P, et al. Nurses perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey. Ther Adv Psychopharmacol. 2015;5(6):339\u201350.","journal-title":"Ther Adv Psychopharmacol"},{"key":"1358_CR32","first-page":"695","volume":"9","author":"A Gonz\u00e1lez-Rodr\u00edguez","year":"2015","unstructured":"Gonz\u00e1lez-Rodr\u00edguez A, Catal\u00e1n R, Penad\u00e9s R, Garcia-Rizo C, Bioque M, Parellada E, et al. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability\u2013a review. Patient Prefer Adherence. 2015;9:695.","journal-title":"Patient Prefer Adherence"},{"issue":"Suppl","key":"1358_CR33","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jad.2012.02.029","volume":"138","author":"A Abdel-Baki","year":"2012","unstructured":"Abdel-Baki A, Ouellet-Plamondon C, Malla A. Pharmacotherapy challenges in patients with first-episode psychosis. J Affect Disord. 2012;138(Suppl):S3\u201314.","journal-title":"J Affect Disord"},{"issue":"8","key":"1358_CR34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40263-013-0083-9","volume":"27","author":"A-S Rauch","year":"2013","unstructured":"Rauch A-S, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013;27(8):637\u201352.","journal-title":"CNS Drugs"},{"issue":"3","key":"1358_CR35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/eip.12027","volume":"7","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Asmal L, Mashile M, Fusar-Poli P. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry. 2013;7(3):247\u201354.","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"1358_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-13-340","volume":"13","author":"PM Llorca","year":"2013","unstructured":"Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13(1):1.","journal-title":"BMC Psychiatry"},{"issue":"5","key":"1358_CR37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","volume":"25","author":"TRE Barnes","year":"2011","unstructured":"Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia. CNS Drugs. 2011;25(5):383\u201399.","journal-title":"CNS Drugs"},{"issue":"2","key":"1358_CR38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1586\/14737167.2014.894463","volume":"14","author":"MH Lafeuille","year":"2014","unstructured":"Lafeuille MH, Dean J, Fastenau J, Panish J, Olson W, Markowitz M, et al. Burden of schizophrenia on selected comorbidity costs. Pharmacoecon Outcome Res. 2014;14(2):259\u201367.","journal-title":"Pharmacoecon Outcome Res"},{"key":"1358_CR39","unstructured":"Status of State Action on the Medicaid Expansion Decision. Kaiser Family Foundation. 2017. http:\/\/kff.org\/health-reform\/state-indicator\/state-activity-around-expanding-medicaid-under-the-affordable-care-act\/ . Accessed Mar 2017."}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-017-1358-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T08:57:05Z","timestamp":1569401825000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-017-1358-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1186\/s12888-017-1358-3","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,2]]},"article-number":"207"}}